Suppr超能文献

乳腺分泌性癌的临床病理特征及肿瘤学结局。

Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast.

机构信息

Department of Thyroid Breast Surgery, Qingdao Chengyang People's Hospital, Qingdao, 266109, Shandong, China.

Department of Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.

出版信息

Sci Rep. 2021 Jul 19;11(1):14738. doi: 10.1038/s41598-021-94351-w.

Abstract

Secretory carcinoma of the breast (SCB) is a rather rare entity of invasive breast cancer, the clinicopathologic characteristics and survival outcomes remain to be elaborated. A retrospective review was conducted in SEER database. A total of 190 SCB patients identified in SEER were eligible for inclusion in the analysis. Median age at diagnosis was 56 years (range 2-96 years). Both sexes and bilateral breast could be affected. Intriguingly, the incidence of SCB tended towards to decreasing in recent decades. Small tumor burden was observed with a mean tumor size of 2.13 cm. In a subgroup with sufficient details, positive staining of estrogen receptor (ER) and progesterone receptor (PR) was 58% and 40%, respectively. The vast majority of patients were of well to moderate differentiation (86.86%) and negative regional lymph nodes involvement (70.71%). Nearly half of the patients took radiotherapy and chemotherapy. Seniors were inclined to have an inferior breast cancer specific survival (BCSS) than their younger counterparts (P = 0.018). Patients underwent breast conserving surgery (BCS) and radiotherapy had much better BCSS than its mastectomy counterparts (P = 0.014). Collectively, SCB is a clinical indolent invasive breast cancer with excellent prognosis. BCS in conjunction with radiotherapy would be a rational alternative for this distinct entity.

摘要

乳腺分泌性癌(SCB)是一种较为罕见的浸润性乳腺癌,其临床病理特征和生存结果仍需进一步阐述。本研究通过 SEER 数据库进行了回顾性分析。SEER 数据库中共纳入 190 例 SCB 患者,符合纳入标准。诊断时的中位年龄为 56 岁(范围 2-96 岁);男女均可发病,也可累及双侧乳房。有趣的是,近几十年来 SCB 的发病率呈下降趋势。肿瘤负荷较小,平均肿瘤大小为 2.13cm。在具有足够详细信息的亚组中,雌激素受体(ER)和孕激素受体(PR)阳性率分别为 58%和 40%。绝大多数患者分化良好至中等(86.86%),且无区域淋巴结受累(70.71%)。近一半的患者接受了放疗和化疗。与年轻患者相比,老年患者的乳腺癌特异性生存(BCSS)较差(P=0.018)。接受保乳手术(BCS)和放疗的患者的 BCSS 明显优于接受乳房切除术的患者(P=0.014)。总之,SCB 是一种临床惰性浸润性乳腺癌,预后良好。BCS 联合放疗可能是这种特殊实体的合理选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce0b/8289843/478946a750f8/41598_2021_94351_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验